Artificial Intelligence Genomics Company Invests Heavily in Drugs
A new breakthrough for the drug industry come with thanks to AI genomics company, Deep Genomics. The company is looking to use machine learning techniques to trace possible genetic causes for disease in order to develop a specialized treatment for the patient.
A new breakthrough for the drug industry come with thanks to AI genomics company, Deep Genomics. The company is looking to use machine learning techniques to trace possible genetic causes for disease in order to develop a specialized treatment for the patient. Deep Genomics is a Canadian-based company that was founded by Brendan Frey, a professor at the University of Toronto who specializes in genomic medicine and machine learning. The company’s main goal is to produce powerful drugs by uncovering just a subtle signal in the genomic data.
The way it works is by using deep learning techniques to analyze the patient’s genomic data. Then, once the researchers have identified one or more genes that are responsible for a disease they can begin to develop a drug that will correct the faulty gene. To begin with, the company will focus purely on early-stage development of drugs for those inherited diseases that result from a single genetic mutation. The mad rush to apply AI to medicine comes partly from the development of new algorithms, but also by the cost effectiveness of sequencing genomes.
“There’s an opening of a new era of data-rich, information-based medicine. There’s a lot of different kinds of data you can obtain. And the best technology we have for dealing with large amounts of data is machine learning and artificial intelligence,” says Frey. “There’s going to be this really massive shake-up of pharmaceuticals,” Frey continues. “In five years or so, the pharmaceutical companies that are going to be successful are going to have a culture of using these AI tools.”
Deep Genomics has also published work demonstrating how deep learning can be used to identify patterns in DNA that may contribute to certain disease including nonpolyposis cancer and spinal muscular atrophy. Other companies that are also pushing forward with the combine machine learning with drug development include a subsidiary of Alphabet called Calico, and a British AI company called BenevolentAI.
More News to Read
- CERN’s CAST Experiment Casts Doubt on the Discovery of Dark Matter
- Getting to Grips With Time Crystals. What is That Really?
- Do We Really Stand a Chance at Finding Alien Life?
- 5 Cosmic Questions Scientists Still Can’t Answer Completely
- Researchers Discover New Role of Immune Cells
Related Coverage
- How Nvidia’s Artificial Intelligence Will Team up With CCTV to Analyse Your Every Move
- Need Someone to Answer Your Emails for you? Just Get Google AI to Do it!
- The Next Phase of Genome-Wide Studies Moves Forward
- Video Search Becomes A Reality!! With Google’s Machine Learning API That Recognizes Objects in Videos
- Artificial Intelligence Helps to Identify Cancer Cells Based on Blood Samples
Don't miss new tech stories on Google
Add TrendinTech once in the Google app and our stories appear in your news suggestions.
Daniel Okafor
Daniel Okafor is the Senior AI Reporter at TrendinTech, where he covers large language models, machine learning research and the practical use of artificial intelligence across business and government. He previously reported on artificial intelligence for MIT Technology Review, covering the labs behind the current generation of frontier models and the policy debates in Washington and Brussels. Daniel holds a Master of Science in Machine Learning from Carnegie Mellon University and follows the research community closely, attending NeurIPS and ICML each year to speak with the people behind the papers. He has a particular interest in evaluation: how models are benchmarked, where those benchmarks fail and what that means for the companies betting on them.
All stories by Daniel Okafor (316)